Aquestive Therapeutics, Inc. Operating Lease, Weighted Average Discount Rate, Percent
Aquestive Therapeutics, Inc. (AQST) had Operating Lease, Weighted Average Discount Rate, Percent of 16.90% as of 2021-03-31, per its 10-Q filed 2021-05-04.
Discontinued › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2021-05-04
- 2021-03-31: Operating Lease, Weighted Average Discount Rate, Percent 16.90%.
- 2020-12-31: Operating Lease, Weighted Average Discount Rate, Percent 16.90%.
- 2020-09-30: Operating Lease, Weighted Average Discount Rate, Percent 16.90%.
- 2020-06-30: Operating Lease, Weighted Average Discount Rate, Percent 16.90%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent |
|---|---|
| 2021-03-31 | 16.90% 10-Q · filed 2021-05-04 |
| 2020-12-31 | 16.90% 10-K · filed 2021-03-09 |
| 2020-09-30 | 16.90% 10-Q · filed 2020-11-04 |
| 2020-06-30 | 16.90% 10-Q · filed 2020-08-04 |
| 2020-03-31 | 16.90% 10-Q · filed 2020-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |